Communicating AI in Pharma: Balancing Innovation and Risk

As the pharma industry explores the potential of AI, it faces a critical challenge: how to maximise opportunities while mitigating risk. A recent Deloitte study highlights both excitement and uncertainty, revealing that 38% of employees have used generative AI tools without formal approval—often due to a lack of clear policies.

For highly regulated sectors like pharma, this presents significant risks. At Dialogue, we believe the key isn’t just setting AI policies but ensuring they are communicated effectively. Here’s how:

1. Establish Clear AI Guidelines—and Share Them Widely

AI policies should be proactive and transparent, outlining:

Which AI tools are approved and restricted
Specific use cases for Medical Affairs, R&D, and Commercial teams
Compliance requirements and best practices

2. Educate and Engage

Employees need more than rules—they need understanding. Regular training, AI use case workshops, and leadership-led communications can build AI literacy and confidence across the organisation.

3. Promote a Culture of Safe AI Innovation

AI policies should empower, not restrict. Encourage teams to explore AI within a structured framework, providing guidance and a space for discussion.

4. Ensure Consistent Messaging Across Functions

From R&D to field teams, everyone should have access to up-to-date guidance on AI use. This alignment reduces risks associated with fragmented or conflicting approaches.

Is your organisation equipped with the right communication strategy to navigate AI effectively?